Litcius/Paper detail

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer

Case Medical Research

2020Case Medical Research17 citationsDOI

Topics & Concepts

PembrolizumabBladder cancerMedicineOncologyCancerInternal medicineImmunotherapyBladder and Urothelial Cancer TreatmentsAmino Acid Enzymes and MetabolismCancer Immunotherapy and Biomarkers